分子診断の世界市場分析:製品別、テストロケーション別(Poc、中央検査室)、技術別(PCR、原位置ハイブリダイゼーション、INAAT、マイクロアレイ、MS、NGS、TMA))、用途別(腫瘍、乳がん、前立腺がん、子宮頸がん、薬理ゲノム学、感染症、MRSA、C。ディフィシル、バンコマイシン耐性腸球菌、カルバペネム耐性、インフルエンザ、RSV、カンジダ、結核、髄膜炎、GITテスト、クラミジア、淋病、HIV、HCV、HBV 、遺伝学、神経学、心臓血管)、セグメント予測...市場調査レポートについてご紹介

【英文タイトル】Molecular Diagnostics Market Analysis By Product, By Test Location (Poc, Central Lab), By Technology (PCR, In-Situ Hybridization, INAAT, Microarrays, MS, NGS, TMA), By Application (Oncology, Breast, Prostate, Cervical, Pharmacogenomics, Infectious Diseases, MRSA, C.Difficile, Vancomycin-Resistant Enterococci, Carbapenem-Resistant, Flu, RSV, Candida, TB, Meningitis, GIT Testing, Chlamydia, Gonorrhea, HIV, HCV, HBV, Genetics, Neurological, Cardiovascular), And Segment Forecasts To 2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Introduction of technological advancements
3.1.1.2 Increasing demand for point of care facilities
3.1.1.3 Growing prevalence of target diseases
3.1.1.4 External funding for executing research and development exercises
3.1.2 Market Restraint Analysis
3.1.2.1 Presence of ambiguous regulatory framework
3.1.2.2 High prices of IVD diagnostic tests
3.2 Penetration & growth prospect mapping
3.3 Molecular Diagnostics – SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis – Porter’s
Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis
4.1 Molecular diagnostics market: Product movement analysis
4.2 Instruments
4.2.1 Instruments market, 2013 – 2024 (USD Million)
4.3 Reagents
4.3.1 Reagents market, 2013 – 2024 (USD Million)
4.4 Others
4.4.1 Others market, 2013 – 2024 (USD Million)
Chapter 5 Market Categorization 2: Test Location Estimates & Trend Analysis
5.1 Molecular diagnostics market: Test Location movement analysis
5.2 Point of Care (PoC)
5.2.1 PoC market, 2013 – 2024 (USD Million)
5.3 Self Test or Over The Counter (OTC)
5.3.1 Self Test or OTC market, 2013 – 2024 (USD Million)
5.4 Central Laboratories
5.4.1 Central laboratories market, 2013 – 2024 (USD Million)
Chapter 6 Market Categorization 3: Technology Estimates & Trend Analysis
6.1 Molecular diagnostics market: Technology movement analysis
6.2 Polymerase Chain Reaction (PCR)
6.2.1 PCR market, 2013 – 2024 (USD Million)
6.2.2 Multiplex PCR market, 2013 – 2024 (USD Million)
6.2.3 Other PCR market, 2013 – 2024 (USD Million)
6.3 In Situ Hybridization
6.3.1 In Situ Hybridization market, 2013 – 2024 (USD Million)
6.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4.1 INAAT market, 2013 – 2024 (USD Million)
6.5 Chips and Microarrays
6.5.1 Chips and microarrays market, 2013 – 2024 (USD Million)
6.6 Mass Spectrometry
6.6.1 Mass spectrometry market, 2013 – 2024 (USD Million)
6.7 Sequencing
6.7.1 Sequencing market, 2013 – 2024 (USD Million)
6.8 Transcription Mediated Amplification (TMA)
6.8.1 TMA market, 2013 – 2024 (USD Million)
6.9 Others
6.9.1 Others market, 2013 – 2024 (USD Million)
Chapter 7 Market Categorization 4: Application Estimates & Trend Analysis
7.1 Molecular diagnostics market: Application movement analysis
7.2 Oncology
7.2.1 Oncology market, 2013 – 2024 (USD Million)
7.2.2 Breast Cancer market, 2013 – 2024 (USD Million)
7.2.3 Prostate Cancer market, 2013 – 2024 (USD Million)
7.2.4 Colorectal Cancer market, 2013 – 2024 (USD Million)
7.2.5 Cervical Cancer market, 2013 – 2024 (USD Million)
7.2.6 Kidney Cancer market, 2013 – 2024 (USD Million)
7.2.7 Liver Cancer market, 2013 – 2024 (USD Million)
7.2.8 Blood Cancer market, 2013 – 2024 (USD Million)
7.2.9 Lung Cancer market, 2013 – 2024 (USD Million)
7.2.10 Others market, 2013 – 2024 (USD Million)
7.3 Pharmacogenomics
7.3.1 Pharmacogenomics market, 2013 – 2024 (USD Million)
7.4 Infectious Diseases
7.4.1 Infectious diseases market, 2013 – 2024 (USD Million)
7.4.2 Methicillin-resistant Staphylococcus Aureus (MRSA) market, 2013 – 2024 (USD Million)
7.4.3 Clostridium difficile market, 2013 – 2024 (USD Million)
7.4.4 Vancomycin-resistant enterococci market, 2013 – 2024 (USD Million)
7.4.5 Carbapenem-resistant bacteria market, 2013 – 2024 (USD Million)
7.4.6 Flu market, 2013 – 2024 (USD Million)
7.4.7 Respiratory syncytial virus (RSV) market, 2013 – 2024 (USD Million)
7.4.8 Candida market, 2013 – 2024 (USD Million)
7.4.9 Tuberculosis and drug-resistant TB market, 2013 – 2024 (USD Million)
7.4.10 Meningitis market, 2013 – 2024 (USD Million)
7.4.11 Gastrointestinal panel market, 2013 – 2024 (USD Million)
7.4.12 Chlamydia market, 2013 – 2024 (USD Million)
7.4.13 Gonorrhea market, 2013 – 2024 (USD Million)
7.4.14 HIV market, 2013 – 2024 (USD Million)
7.4.15 Hepatitis C market, 2013 – 2024 (USD Million)
7.4.16 Hepatitis B market, 2013 – 2024 (USD Million)
7.4.17 Others market, 2013 – 2024 (USD Million)
7.5 Genetic testing
7.5.1 Genetic testing market, 2013 – 2024 (USD Million)
7.5.2 Newborn screening market, 2013 – 2024 (USD Million)
7.5.3 Predictive and presymptomatic testing market, 2013 – 2024 (USD Million)
7.5.4 Other market, 2013 – 2024 (USD Million)
7.6 Neurological diseases
7.6.1 Neurological diseases market, 2013 – 2024 (USD Million)
7.7 Cardiovascular diseases
7.7.1 Cardiovascular diseases market, 2013 – 2024 (USD Million)
7.8 Microbiology
7.8.1 Microbiology market, 2013 – 2024 (USD Million)
Chapter 8 Market Categorization 5: Regional Estimates & Trend Analysis, by Product, Test Location, Technology & Application
8.1 Molecular diagnostics market share by region, 2013 & 2024
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 UK
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Belgium
8.3.7 Switzerland
8.3.8 Netherlands
8.3.9 Poland
8.3.10 Austria
8.3.11 Greece
8.3.12 Sweden
8.3.13 Turkey
8.3.14 Finland
8.4 Asia Pacific
8.4.1 India
8.4.2 China
8.4.3 Japan
8.4.4 Sri Lanka
8.4.5 Malaysia
8.4.6 Australia
8.4.7 New Zealand
8.4.8 Thailand
8.4.9 Vietnam
8.4.10 Ireland
8.4.11 Singapore
8.5 Latin America
8.5.1 Mexico
8.5.2 Brazil
8.5.3 Chile
8.5.4 Peru
8.5.5 Colombia
8.5.6 Argentina
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Jordan
8.6.4 UAE
8.6.5 Qatar
8.6.6 Nigeria
8.6.7 Egypt
Chapter 9 Competitive Landscape
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Abbott Molecular
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Alere, Inc.
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Bayer Healthcare AG
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Becton, Dickinson and Company
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 bioMérieux SA
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 Bio-Rad Laboratories, Inc.
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Cepheid
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Dako
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Danaher Corporation
9.3.9.1 Company Overview
9.3.9.2 Beckman Coulter
9.3.9.3 Leica Biosystems
9.3.9.4 Financial Performance
9.3.9.5 Product Benchmarking
9.3.9.6 Strategic Initiatives
9.3.9.7 Strategic Initiatives of Beckman Coulter Inc.
9.3.9.8 Strategic Initiatives of Leica Biosystems
9.3.10 Hologic, Inc. (Gen Probe)
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Johnson & Johnson Services, Inc.
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Novartis AG (Grifols)
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives
9.3.13 Qiagen
9.3.13.1 Company Overview
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 F. Hoffmann-La Roche Ltd
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 Siemens Healthcare GmbH
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Sysmex Corporation
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives


【レポート販売概要】

■ タイトル:分子診断の世界市場分析:製品別、テストロケーション別(Poc、中央検査室)、技術別(PCR、原位置ハイブリダイゼーション、INAAT、マイクロアレイ、MS、NGS、TMA))、用途別(腫瘍、乳がん、前立腺がん、子宮頸がん、薬理ゲノム学、感染症、MRSA、C。ディフィシル、バンコマイシン耐性腸球菌、カルバペネム耐性、インフルエンザ、RSV、カンジダ、結核、髄膜炎、GITテスト、クラミジア、淋病、HIV、HCV、HBV 、遺伝学、神経学、心臓血管)、セグメント予測
■ 英文:Molecular Diagnostics Market Analysis By Product, By Test Location (Poc, Central Lab), By Technology (PCR, In-Situ Hybridization, INAAT, Microarrays, MS, NGS, TMA), By Application (Oncology, Breast, Prostate, Cervical, Pharmacogenomics, Infectious Diseases, MRSA, C.Difficile, Vancomycin-Resistant Enterococci, Carbapenem-Resistant, Flu, RSV, Candida, TB, Meningitis, GIT Testing, Chlamydia, Gonorrhea, HIV, HCV, HBV, Genetics, Neurological, Cardiovascular), And Segment Forecasts To 2024
■ 発行日:2016年9月13日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707558
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。